Icahn No Longer Intends to Nominate an Opposing MedImmune (MEDI) Board

Investing

Published: April 16, 2007 11:03 am

From 13D Tracker

Carl Icahn said now that MedImmune’s (Nasdaq: MEDI) board has announced it intends to sell the company, he no longer intends to put forth an opposition slate. Icahn said he will closely monitoring the Company’s efforts and reserves the right to launch a proxy contest in the event that MedImmune does not successfully complete the sale transaction.

Several weeks ago Icahn informed the company he believed the best course of action was to put the company up for sale and planed to nominate an opposing slate at the upcoming 2007 annual meeting.

Cash Back Credit Cards Have Never Been This Good

Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.

Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.